ARWR

Arrowhead Pharmaceuticals is a biotech company focused on developing RNA interference (RNAi) therapeutics to silence disease-causing genes. Its proprietary TRiM™ platform targets a wide range of diseases, including cardiovascular, liver, metabolic, and pulmonary conditions. With late-stage programs like plozasiran for severe hypertriglyceridemia and strategic partnerships with Amgen, Takeda, and Sarepta, the company is aiming to advance 20 therapies to market or clinical trials by 2025.